Coverage Decision

Coverage Decision in Health Technology Funding

A coverage decision settles whether a health system or insurer will pay for a medicine, device, test or procedure, and may limit that funding to certain patients or attach terms to it. Licensing allows a product to be sold, but patients in tax-funded systems and insured populations usually reach it only after a payer has decided to fund it, so the coverage decision is the point at which health technology assessment and cost-effectiveness analysis turn into access. The answer is often more than a plain yes or no, because a decision may fund a technology only for a subgroup, only at a negotiated price or only while further evidence is collected. European Union law calls the same national ruling a reimbursement decision.

What a coverage decision settles

A coverage decision is a specific type of decision with a defined scope. It names the technology and indication, the eligible population, any clinical or service conditions, and the date from which funding applies. The underlying evidence is about a technology compared with current care in a stated population, so a decision that funds a different group from the one assessed has no evidential basis for that group.

Coverage is separate from price and from payment. United States law defines a Medicare national coverage determination as a determination of whether a particular item or service is covered nationally, and expressly excludes the code assigned to it and the amount paid for it. The general rules a payer applies across many technologies make up its coverage policy, and a coverage decision is a single ruling made under those rules.

Who makes the decision and how binding it is

Systems differ in whether the body that assesses the evidence also holds the money. Fontrier, Visintin and Kanavos mapped 63 HTA bodies across 32 countries in the European Union, the UK, Canada and Australia and found that 52% had an advisory role and that 81% of HTA outcomes were not legally binding. Where a recommendation is non-binding, they note, a negative recommendation does not necessarily lead to a negative coverage decision.

In England the recommendation carries legal force. Under regulation 7 of the NICE regulations of 2013, a technology appraisal recommendation can require relevant health bodies to provide funding, those bodies must comply, and funding must normally be in place within 3 months of publication unless NICE specifies a longer period, for example where training or infrastructure is needed first. In Australia, the Pharmaceutical Benefits Advisory Committee states that no new medicine can be listed on the Pharmaceutical Benefits Scheme unless it makes a positive recommendation, taking account of clinical effectiveness, safety and cost-effectiveness compared with other treatments.

Medicare in the United States limits coverage to items and services that are reasonable and necessary for diagnosis or treatment. The Centers for Medicare and Medicaid Services (CMS) issues national coverage determinations through an evidence-based process with public comment, and where no national determination exists, local contractors may decide coverage. Federal law also bars the Secretary from using a dollars-per-QALY threshold to determine Medicare coverage, so cost per QALY cannot serve as the decision rule there.

Across the European Union, Regulation (EU) 2021/2282 has applied since 12 January 2025 and introduces joint clinical assessments of relative effectiveness. Article 1 states that the Regulation does not interfere with the exclusive national competence of Member States for pricing and reimbursement decisions, so the coverage decision itself stays national.

The economic test behind a positive decision

Where cost-effectiveness counts, the question is whether the health gained from funding the technology exceeds the health lost elsewhere because the money is spent on it, which is its opportunity cost. Incremental net monetary benefit expresses this in money terms.

$$\text{INMB} = \lambda \, \Delta E - \Delta C$$

where $\Delta E$ is the incremental QALYs per patient, $\Delta C$ is the incremental cost per patient and $\lambda$ is the value placed on one QALY. A positive INMB means the technology adds more value than it displaces at that value of $\lambda$.

The NICE manual (PMG36, last updated 13 October 2026) states that below a most plausible ICER of GBP 25,000 per QALY gained, the decision to recommend is normally based on the cost-effectiveness estimate. Between GBP 25,000 and GBP 35,000 the committee refers explicitly to factors such as uncertainty, uncaptured benefits and health inequalities, and above GBP 35,000 it needs an increasingly stronger case. When decision-making modifiers such as severity are applied, net health benefit is presented at both GBP 25,000 and GBP 35,000 per QALY to show the opportunity cost.

Real decisions are not a mechanical application of a cost-effectiveness threshold. Tranvåg and colleagues studied Norwegian drug coverage decisions from 2014 to 2019, when 138 of 188 appraised drugs (73%) were approved. In the 83 decisions with complete ICER and severity data, they found that the ICER based on negotiated prices, adjusted for thresholds that rise with disease severity, best predicted approval, which shows severity and price negotiation entering the decision alongside cost-effectiveness.

Affordability is a separate test from value for money. In England, NHS England may ask for longer to implement the funding requirement when a medicine's net budget impact is expected to exceed GBP 40 million a year in any of its first 3 years, and it offers commercial discussions with the company before doing so.

Types of decision beyond yes and no

The NICE manual sets out a range of recommendation types. A technology may be recommended; recommended only in specific circumstances, such as a subgroup or a particular setting (an optimised recommendation); recommended with managed access, for medicines only; recommended only in a research context; or not recommended. Managed access is for medicines with plausible potential to be cost effective whose evidence is too uncertain, where new evidence could be collected within a reasonable timeframe of up to 5 years. During that period the medicine is funded from dedicated managed access funds at a temporary price and is not regarded as established NHS practice.

Medicare has a comparable route. CMS may cover an item or service under a national coverage determination only in the context of a clinical study, known as coverage with evidence development, and the cycle is complete when CMS reconsiders the determination and removes study participation as a condition of coverage. Both approaches are forms of managed entry agreement, and their value depends on whether the extra evidence could change the decision, which is what value of information analysis estimates.

Worked example of restricting coverage to a subgroup

The following numbers are illustrative. A payer considers a new medicine for 10,000 eligible patients a year. Compared with standard care it costs GBP 12,000 more per patient treated, with all costs assumed to fall in the first year, and gains 0.30 QALYs on average. The gain is 0.60 QALYs in the 40% of patients who carry a biomarker and 0.10 QALYs in the other 60%, so the average is 0.4 × 0.60 + 0.6 × 0.10 = 0.30.

1. Full population. Total incremental cost is 10,000 × 12,000 = GBP 120 million, and total QALYs gained are 10,000 × 0.30 = 3,000, so the ICER is 120,000,000 / 3,000 = GBP 40,000 per QALY. The INMB per patient is 0.30 × 25,000 − 12,000 = −4,500 at GBP 25,000 and 0.30 × 35,000 − 12,000 = −1,500 at GBP 35,000, negative at both values.

2. Biomarker-positive patients only. Restriction requires testing everyone, at an assumed GBP 500 per test. The test costs 10,000 × 500 = GBP 5 million and treatment of the 4,000 positive patients costs 4,000 × 12,000 = GBP 48 million, a total of GBP 53 million. QALYs gained are 4,000 × 0.60 = 2,400.

$$\text{ICER} = \frac{53{,}000{,}000}{2{,}400} = 22{,}083$$

where the numerator is the total incremental cost in GBP of testing and treatment and the denominator is the total QALYs gained. At GBP 25,000 per QALY the INMB is 2,400 × 25,000 − 53,000,000 = GBP 7 million, so the restricted decision adds value.

3. A price alternative. Funding the full population would reach an INMB of zero at GBP 25,000 per QALY if the incremental cost per patient fell to 0.30 × 25,000 = GBP 7,500, a reduction of GBP 4,500 or 37.5%. At that price the restricted option would still give the higher INMB, 2,400 × 25,000 − (5,000,000 + 4,000 × 7,500) = GBP 25 million against zero, so the price cut makes full coverage acceptable but not the better choice.

4. Interpretation. The restricted decision is the optimised recommendation in miniature, with a value that depends on the test identifying the right patients in practice. Its annual cost of GBP 53 million would still exceed the GBP 40 million level at which NHS England may seek longer to implement funding, so affordability could delay access even after a positive decision on value.

How a coverage decision differs from nearby concepts

HTA assesses the evidence and, where the HTA body is advisory, ends in a recommendation to the payer. Appraisal is the step in which a committee weighs that evidence, while the coverage decision is the funding ruling that follows, made by the same body only where the law gives it that power. Reimbursement concerns the payment made for covered care.

Several narrower decisions apply a coverage decision or follow from it. A formulary lists the medicines a plan covers, and prior authorisation checks an individual patient against the coverage criteria before care is given. The benefit package is the sum of a system's coverage decisions at a point in time.

Where coverage decisions are misread

A coverage decision is only as good as the assessment behind it and the implementation after it. The common errors arise from treating one stage of the process as the whole.

1. Marketing authorisation means funding. A licence allows a product to be sold, while coverage is a separate decision on whether to pay for it.
2. A positive HTA recommendation is the final word. In advisory systems the payer may decide otherwise, as the 81% non-binding figure shows.
3. A cost-effective technology is affordable. The worked example passes the value test but still has a budget impact large enough to slow funding.
4. Non-coverage means the technology does not work. A refusal can reflect price, uncertainty or opportunity cost rather than a lack of clinical benefit.
5. Conditional coverage is permanent. Managed access and coverage with evidence development end in a reconsideration, and NICE states that a medicine not then recommended stops being available to people who have not yet started it.
6. The list price is the decision price. Negotiated prices can be confidential, as in the Norwegian decisions analysed by Tranvåg and colleagues, so a published ICER may not be the one the decision rested on.

Sources

• Centers for Medicare and Medicaid Services. Coverage with evidence development. Baltimore: CMS; accessed 10 October 2026. https://www.cms.gov/medicare/coverage/evidence
• Centers for Medicare and Medicaid Services. Medicare coverage determination process. Baltimore: CMS; accessed 10 October 2026. https://www.cms.gov/medicare/coverage/determination-process
• European Parliament and Council. Regulation (EU) 2021/2282 of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU. Official Journal of the European Union. 2021;L 458:1. https://eur-lex.europa.eu/eli/reg/2021/2282/oj
• European Commission. Implementation of the Regulation on health technology assessment. Brussels: European Commission; accessed 10 October 2026. https://health.ec.europa.eu/health-technology-assessment/implementation-regulation-health-technology-assessment_en
• Fontrier AM, Visintin E, Kanavos P. Similarities and differences in health technology assessment systems and implications for coverage decisions: evidence from 32 countries. PharmacoEconomics Open. 2022;6(3):315-328. https://doi.org/10.1007/s41669-021-00311-5
• National Institute for Health and Care Excellence. NICE technology appraisal and highly specialised technologies guidance: the manual (PMG36). London: NICE; 2022, last updated 13 October 2026. https://www.nice.org.uk/process/pmg36
• Pharmaceutical Benefits Scheme. Pharmaceutical Benefits Advisory Committee (PBAC) membership. Canberra: Australian Government Department of Health, Disability and Ageing; accessed 10 October 2026. https://www.pbs.gov.au/industry/listing/participants/pbac
• The National Institute for Health and Care Excellence (Constitution and Functions) and NHS England (Information Functions) Regulations 2013, SI 2013/259, regulation 7. https://www.legislation.gov.uk/uksi/2013/259/regulation/7
• Tranvåg EJ, Haaland ØA, Robberstad B, Norheim OF. Appraising drugs based on cost-effectiveness and severity of disease in Norwegian drug coverage decisions. JAMA Network Open. 2022;5(6):e2219503. https://doi.org/10.1001/jamanetworkopen.2022.19503
• United States Code, Title 42, sections 1320e-1, 1395ff(f) and 1395y(a). Ithaca, NY: Legal Information Institute, Cornell Law School; accessed 10 October 2026. https://www.law.cornell.edu/uscode/text/42/1395y